Market Overview

INVESTOR ALERT: Brower Piven Commences an Investigation into the Proposed Sale of Albany Molecular Research, Inc. and Encourages Investors to Contact the Firm for Additional Information

Share:





The securities litigation law firm of Brower Piven, A Professional
Corporation, has commenced an investigation into possible breaches of
fiduciary duty and other violations of state law by the Board of
Directors of Albany Molecular Research, Inc. (NASDAQ:AMRI) ("AMRI" or
the "Company") relating to the proposed buyout of AMRI by The Carlyle
Group.

Under the terms of the agreement, AMRI shareholders are anticipated to
receive $21.75 in cash for each share of AMRI common stock held. The
firm's investigation seeks to determine, among other things, whether the
Company's Board of Directors failed to satisfy their duties to
shareholders, including whether the Board adequately pursued
alternatives to the acquisition and whether the Board obtained the best
price possible for the Company's shares of common stock.

If you currently own common stock of AMRI and believe that the proposed
buyout price is too low, and you would like to learn more about the
investigation being conducted by Brower Piven, please visit our website
at http://www.browerpiven.com/currentinvestigations.html.
You may also request more information by contacting Brower Piven either
by email at hoffman@browerpiven.com
or by telephone at (410) 415-6616.

Attorneys at Brower Piven have extensive experience in litigating
securities and other class action cases and have been advocating for the
rights of shareholders since the 1980s.

View Comments and Join the Discussion!
 
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com